Evercore ISI Group Reinstates Outperform on Travere Therapeutics, Announces $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko has reinstated Travere Therapeutics (NASDAQ:TVTX) with an Outperform rating and announced a $30 price target.
September 06, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics has been reinstated with an Outperform rating by Evercore ISI Group, with a price target of $30.
The reinstatement of an Outperform rating by a reputable analyst group like Evercore ISI Group is a positive signal for Travere Therapeutics. The $30 price target suggests a bullish outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100